Accelerating Cardiology Biologics Prior Auth for Specialty Cardiovascular Therapies

The Unique PA Landscape for Cardiology Biologics

Cardiology's increasing reliance on advanced specialty drugs, including biologics such as PCSK9 inhibitors, introduces a complex layer of prior authorization. While traditional biologics (e.g., TNF inhibitors) are common in other specialties, PCSK9 inhibitors represent a key biologic class within cardiovascular care. Other high-cost specialty drugs like sacubitril/valsartan, SGLT2 inhibitors for heart failure, and mavacamten, though not all biologics, share similar PA complexities, demanding precise documentation and adherence to payer protocols.

Key Challenges in Cardiology Specialty Drug Prior Authorization

• **Indication-Specific Criteria:** Strict requirements for drugs like PCSK9 inhibitors (e.g., LDL levels on maximum tolerated statin therapy plus ezetimibe trial).
• **Payer-Specific Step Therapy:** Navigating diverse payer mandates for prior lines of therapy before authorizing specialty cardiovascular drugs.
• **Biosimilar Substitution Policies:** Adhering to evolving payer policies regarding biosimilar alternatives for biologic agents.
• **Periodic Re-authorization:** Managing recurring PA submissions, typically on 6 or 12-month cycles, requiring continuous disease activity and response documentation.
• **Medical vs. Pharmacy Benefit Routing:** Determining the correct benefit channel for a drug, which can vary by administration method and payer.

Navigating Payer and Specialty Benefit Manager Requirements

Cardiology prior authorization frequently involves specialty benefit-management vendors, particularly for advanced cardiac imaging and, by extension, complex specialty drugs. Vendors such as Carelon MBM, eviCore (or successor entities), and NIA/Magellan often manage these requests, requiring practices to engage with vendor-specific portals and policy criteria rather than direct payer channels. Klivira's platform automatically identifies and routes requests to the appropriate entity, whether payer-direct or through a specialty benefit manager.

Critical Documentation for Cardiology Biologics and Specialty Drugs

• **PCSK9 Inhibitors:** Documentation of LDL-C levels, history of maximum tolerated statin therapy, and ezetimibe trial.
• **Sacubitril/Valsartan (Entresto):** Evidence of Heart Failure with Reduced Ejection Fraction (HFrEF).
• **SGLT2 Inhibitors for HF:** Ejection fraction documentation or criteria for Heart Failure with Preserved Ejection Fraction (HFpEF).
• **Optimal Medical Therapy:** For many cardiovascular therapies, documentation of adherence to guideline-directed medical therapy (GDMT) for an adequate duration.
• **Relevant Clinical Guidelines:** Adherence to ACC/AHA guidelines, which often inform payer policy for specialty cardiovascular drugs.

Klivira's Automated Approach to Cardiology Biologics PA

Klivira integrates directly with your EMR via SMART on FHIR, automating the complex **cardiology biologics prior auth** workflow. Our platform performs indication classification, pulls prior-line therapy history, and applies payer-specific biosimilar substitution logic. For critical documentation, Klivira extracts relevant clinical data such as LDL levels, ejection fraction, and medication history, ensuring comprehensive submissions. We also manage periodic re-authorization cycles, reducing manual effort and ensuring continuity of care.

Optimizing Workflow and Patient Access for Cardiovascular Care

By automating the prior authorization process for cardiology biologics and other specialty cardiovascular drugs, Klivira empowers cardiac care teams to focus on patient care rather than administrative tasks. Our solution aims to significantly reduce turnaround times, minimize denial rates stemming from documentation gaps or step-therapy non-compliance, and accelerate patient access to essential, high-cost therapies. This operational efficiency translates directly into improved revenue cycle performance and enhanced patient outcomes.